Neurocrine Biosciences, Inc.
US ˙ NasdaqGS ˙ US64125C1099

SecurityNBIX / Neurocrine Biosciences, Inc.
InstitutionMan Group plc
Latest Disclosed Ownership415,909 shares
Latest Disclosed Value $ 54,791,852
Man Group plc reports 79.88% increase in ownership of NBIX / Neurocrine Biosciences, Inc.

On May 15, 2026 - Man Group plc filed a 13F-HR form disclosing ownership of 415,909 shares of Neurocrine Biosciences, Inc. (US:NBIX) valued at $54,791,852 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 231,210 shares of Neurocrine Biosciences, Inc.. This represents a change in shares of 79.88% during the quarter. The current value of the position is $68,670,735 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 415,909 184,699 79.88 54,792 67.09 0.0994
2026-02-17 2025-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 231,210 150,378 186.04 32,793 188.99 0.0557
2025-11-14 2025-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 80,832 33,606 71.16 11,347 91.19 0.0197
2025-08-14 2025-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 47,226 -52,962 -52.86 5,936 -46.44 0.0113
2025-05-15 2025-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 100,188 -44,976 -30.98 11,081 -44.08 0.0281
2025-02-14 2024-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 145,164 -151,015 -50.99 19,815 -41.94 0.0521
2024-11-14 2024-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 296,179 62,954 26.99 34,126 6.28 0.0889
2024-08-14 2024-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 233,225 -56,536 -19.51 32,108 -19.66 0.0811
2024-05-15 2024-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 289,761 -28,673 -9.00 39,964 -4.75 0.1008
2024-02-14 2023-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 318,434 41,957 11.50 0.1168
2023-11-14 2023-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 37,630 -36.73 0.1166
2023-08-14 2023-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 630,747 59,479 -8.09 0.1835
2023-05-15 2023-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 64,712 71.47 0.2302
2023-02-14 2022-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 315,970 210,283 198.97 37,739 236.20 0.1353
2022-11-14 2022-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 105,687 11,225 304.94 0.0521
2022-08-15 2022-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 2,772 -88.04 0.0117
2022-05-16 2022-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 247,313 13,750 5.89 23,186 16.55 0.0807
2022-02-14 2021-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 233,563 233,563 19,893 0.0640
2021-05-17 2021-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 0 -2,107 -100.00 0 -100.00
2021-02-16 2020-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 2,107 -186,516 -98.88 202 -98.89 0.0009
2020-11-16 2020-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 188,623 93,819 98.96 18,138 56.82 0.0714
2020-08-14 2020-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 94,804 47,147 98.93 11,566 180.46 0.0583
2020-05-15 2020-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 47,657 35,019 277.09 4,124 203.68 0.0267
2020-02-18 2019-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 12,638 5,099 67.63 1,358 100.00 0.0045
2019-11-14 2019-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 7,539 -48,564 -86.56 679 -85.67 0.0025
2019-08-14 2019-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 56,103 -30,075 -34.90 4,737 -37.60 0.0171
2019-05-15 2019-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 86,178 -69,706 -44.72 7,591 -31.81 0.0288
2019-02-14 2018-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 155,884 141,180 960.15 11,132 516.05 0.0495
2018-11-14 2018-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 14,704 -2,620 -15.12 1,807 6.17 0.0066
2018-08-14 2018-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 17,324 -5,125 -22.83 1,702 -8.59 0.0070
2018-05-15 2018-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 22,449 22,449 1,862 0.0085
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.